Your browser is no longer supported. Please, upgrade your browser.
CSII Cardiovascular Systems, Inc. monthly Stock Chart
Cardiovascular Systems, Inc.
Index- P/E- EPS (ttm)-0.67 Insider Own2.80% Shs Outstand40.12M Perf Week-0.11%
Market Cap1.44B Forward P/E- EPS next Y-0.05 Insider Trans-0.22% Shs Float38.71M Perf Month-7.69%
Income-23.50M PEG- EPS next Q-0.06 Inst Own94.40% Short Float2.54% Perf Quarter6.23%
Sales232.60M P/S6.19 EPS this Y77.20% Inst Trans0.39% Short Ratio2.95 Perf Half Y-8.86%
Book/sh6.94 P/B5.09 EPS next Y72.20% ROA-8.40% Target Price44.25 Perf Year-21.58%
Cash/sh5.46 P/C6.46 EPS next 5Y- ROE-11.40% 52W Range26.00 - 55.22 Perf YTD-27.37%
Dividend- P/FCF- EPS past 5Y5.20% ROI-9.30% 52W High-36.09% Beta1.20
Dividend %- Quick Ratio5.60 Sales past 5Y5.40% Gross Margin79.10% 52W Low35.73% ATR1.39
Employees779 Current Ratio6.20 Sales Q/Q-6.20% Oper. Margin-9.70% RSI (14)45.67 Volatility2.51% 4.26%
OptionableYes Debt/Eq0.08 EPS Q/Q68.50% Profit Margin-10.10% Rel Volume0.45 Prev Close35.44
ShortableYes LT Debt/Eq0.08 EarningsNov 04 AMC Payout- Avg Volume333.48K Price35.29
Recom2.20 SMA20-1.09% SMA50-3.51% SMA200-0.72% Volume150,473 Change-0.42%
Nov-05-20Reiterated Needham Buy $44 → $47
Jul-22-20Initiated Northland Capital Outperform $40
Jul-17-20Initiated Barclays Overweight
Jun-11-20Upgrade Needham Hold → Buy
Apr-07-20Initiated Oppenheimer Outperform $47
Oct-18-19Initiated Guggenheim Buy
Apr-11-19Downgrade BofA/Merrill Buy → Underperform $51 → $42
Aug-22-18Initiated Stifel Buy $45
Jun-27-18Upgrade BofA/Merrill Underperform → Buy
Dec-15-17Downgrade Needham Buy → Hold
Oct-26-17Reiterated Needham Buy $37 → $36
Sep-22-17Initiated Raymond James Mkt Perform
Jun-21-17Downgrade BofA/Merrill Neutral → Underperform
Jan-30-17Initiated Lake Street Buy $40
Jan-26-17Reiterated Needham Buy $27 → $32
Oct-07-16Resumed JMP Securities Mkt Outperform
Aug-22-16Upgrade Leerink Partners Mkt Perform → Outperform
Aug-04-16Upgrade BofA/Merrill Underperform → Neutral
Aug-04-16Reiterated Needham Buy $23 → $27
Jun-29-16Reiterated Needham Buy $20 → $23
Nov-11-20 07:00AM  
Nov-06-20 08:46AM  
Nov-04-20 08:31PM  
Nov-03-20 10:08AM  
Oct-28-20 12:32PM  
Oct-21-20 07:00AM  
Oct-14-20 08:00AM  
Oct-12-20 01:00PM  
Oct-07-20 07:00AM  
Sep-15-20 10:01AM  
Sep-03-20 11:31AM  
Aug-20-20 04:05PM  
Aug-19-20 11:38AM  
Aug-17-20 02:55AM  
Aug-06-20 10:43AM  
Aug-05-20 01:31AM  
Aug-04-20 06:45PM  
Aug-03-20 12:48PM  
Jul-28-20 12:33PM  
Jul-27-20 04:05PM  
Jul-22-20 09:35AM  
Jul-14-20 07:00AM  
Jul-09-20 05:23PM  
Jul-05-20 05:05PM  
Jun-18-20 08:40AM  
Jun-11-20 04:05PM  
Jun-10-20 01:25PM  
Jun-09-20 10:32PM  
May-28-20 05:06AM  
May-06-20 10:44AM  
May-05-20 06:45PM  
Apr-28-20 12:33PM  
Apr-21-20 07:00AM  
Apr-14-20 01:34PM  
Mar-06-20 11:30AM  
Feb-20-20 08:00AM  
Feb-18-20 05:00PM  
Feb-17-20 09:31AM  
Feb-11-20 05:24PM  
Feb-06-20 08:14AM  
Feb-05-20 05:55PM  
Jan-29-20 12:31PM  
Jan-20-20 09:49AM  
Jan-18-20 12:41PM  
Jan-15-20 07:00AM  
Dec-20-19 06:01AM  
Dec-17-19 08:22AM  
Dec-16-19 07:00AM  
Dec-11-19 11:02PM  
Dec-02-19 08:40PM  
Nov-28-19 09:31AM  
Nov-12-19 05:00PM  
Nov-05-19 07:00AM  
Oct-30-19 08:27AM  
Oct-29-19 06:35PM  
Oct-26-19 12:47PM  
Oct-21-19 06:01AM  
Oct-08-19 04:05PM  
Oct-01-19 03:30PM  
Sep-24-19 07:00AM  
Sep-06-19 09:53AM  
Sep-05-19 09:31AM  
Aug-28-19 07:00AM  
Aug-23-19 07:48AM  
Aug-16-19 04:45PM  
Aug-15-19 09:44AM  
Aug-12-19 04:05PM  
Aug-08-19 09:50AM  
Aug-07-19 07:00AM  
Aug-06-19 07:25PM  
Aug-05-19 07:00PM  
Jul-30-19 10:38AM  
Jul-25-19 05:37PM  
Jul-23-19 12:14PM  
Jul-16-19 07:00AM  
Jul-01-19 08:57AM  
Jun-28-19 08:49AM  
Jun-26-19 09:36AM  
Jun-25-19 03:42PM  
Jun-24-19 09:31AM  
Jun-20-19 09:53AM  
Cardiovascular Systems, Inc., a medical device company, develops and commercializes various devices to treat peripheral and coronary artery diseases in the United States. The company offers peripheral artery disease products, which are catheter-based platforms to treat a range of plaque types in above and below the knee leg arteries, including calcified plaque, as well as address various limitations related with surgical, catheter, and pharmacological treatment alternatives; and peripheral support products. It also provides Diamondback 360 Coronary orbital atherectomy systems (OAS), a coronary artery disease (CAD) product designed to facilitate stent delivery in patients with CAD who are acceptable candidates for percutaneous transluminal coronary angioplasty or stenting due to severely calcified coronary artery lesions. The company was founded in 1989 and is headquartered in St. Paul, Minnesota.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sedo SandraChief Compliance OfficerAug 24Sale31.942,91493,06767,467Aug 26 04:34 PM
Rosenstein AlexanderGeneral Counsel & Corp. Sec.Aug 24Sale31.944,692149,85384,145Aug 26 04:34 PM
Sedo SandraChief Compliance OfficerAug 18Sale32.8944014,47174,280Aug 20 04:48 PM
Paulsen ErikDirectorAug 17Buy32.852006,570200Aug 19 08:46 AM
Robb Rhonda J.Chief Operating OfficerAug 14Buy31.971,00031,969167,106Aug 17 11:31 AM
Aronson Martha GoldbergDirectorAug 13Buy32.223,00096,6556,000Aug 17 11:31 AM
Ward Scott R.Chairman and CEOAug 13Buy32.191,00032,187581,332Aug 17 11:30 AM
Points Jeffrey S.Chief Financial OfficerAug 13Buy32.011,00032,01085,841Aug 17 11:30 AM
Rosenstein AlexanderGeneral Counsel & Corp. Sec.Aug 13Sale31.9668521,89393,491Aug 17 04:57 PM
Points Jeffrey S.Chief Financial OfficerFeb 12Sale42.183,000126,53650,613Feb 14 04:15 PM
Robb Rhonda J.Chief Operating OfficerFeb 12Sale42.293,600152,246120,510Feb 14 04:14 PM
Hastings John M.VP Manufacturing & OperationsFeb 12Sale42.115,357225,58529,173Feb 14 04:13 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.